Psoriatic Arthritis Therapeutics Market Report
First published: 21 October 2024 | Last updated: 25 May 2026 | Report Code: psoriatic-arthritis-therapeutics
Psoriatic Arthritis Therapeutics Market — USD $12 Billion in 2023, Growing to USD 27.85null by 2033 at 8.5% CAGR
This report provides a comprehensive analysis of the Psoriatic Arthritis Therapeutics market, showcasing market size, trends, and forecasts from 2023 to 2033, along with a detailed segmentation, regional insights, and key players in the industry.
Key Takeaways
- Global market expands from $12.00 Billion in 2023 to $27.85 Billion by 2033 at an 8.5% CAGR.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Therapeutic mix includes DMARDs, NSAIDs, and corticosteroids across oral, injectable, and topical routes.
- Leading companies in the space include AbbVie, Johnson & Johnson, Amgen, and Novartis.
- Growth is supported by innovation in biologics, increasing disease awareness, and broader access to advanced therapies.
Psoriatic Arthritis Therapeutics Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. The Psoriatic Arthritis Therapeutics Market Report outlines a decade of robust expansion driven by advances in targeted therapies and growing clinical awareness. The market value rises from $12.00 Billion in 2023 to $27.85 Billion by 2033 at an 8.5% CAGR for 2023 to 2033. Demand is supported by the adoption of biologics, development of next-generation disease-modifying agents, and expanded care access in multiple regions. The industry structure covers drug classes such as Disease-Modifying Antirheumatic Drugs (DMARDs), Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), and corticosteroids, and accounts for oral, injectable, and topical delivery modes. Market activity is shaped by established biopharma players including AbbVie, Johnson & Johnson, Amgen, and Novartis, alongside ongoing trials and pipeline developments. Regional performance varies, with North America holding the largest market value through the forecast. This report synthesizes primary interviews and secondary sources to present trend analysis, segment performance, and competitive positioning for stakeholders planning investment or strategic initiatives.
Key Growth Drivers
- Rising uptake of biologics and targeted therapies expanding treatment options and patient response rates.
- Increasing diagnosis and awareness of psoriatic arthritis leading to higher treatment initiation and continuity.
- Broader availability of biosimilars improving access and affordability in multiple markets.
- Ongoing clinical research and pipeline activity introducing novel mechanisms of action and formulation improvements.
- Expansion of distribution channels, including hospital and online pharmacies, facilitating patient access.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $12.00 Billion |
| CAGR (2023-2033) | 8.5% |
| 2033 Market Size | $27.85 Billion |
| Top Companies | AbbVie, Johnson & Johnson, Amgen, Novartis |
| Published Date | 21 October 2024 |
| Last Modified Date | 25 May 2026 |
Psoriatic Arthritis Therapeutics Market Overview
Customize Psoriatic Arthritis Therapeutics Market Report market research report
- ✔ Get in-depth analysis of Psoriatic Arthritis Therapeutics market size, growth, and forecasts.
- ✔ Understand Psoriatic Arthritis Therapeutics's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Psoriatic Arthritis Therapeutics
What is the Market Size & CAGR of Psoriatic Arthritis Therapeutics Market Report market in 2023?
Psoriatic Arthritis Therapeutics Industry Analysis
Psoriatic Arthritis Therapeutics Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Psoriatic Arthritis Therapeutics Market Report Market Analysis Report by Region
Europe Psoriatic Arthritis Therapeutics Market Report:
Europe grows from $3.19 Billion in 2023 to $7.41 Billion in 2033. Market progress is supported by increasing acceptance of biosimilars, widespread clinical guidelines, and a strong presence of established biopharma companies conducting regional trials and commercialization.Asia Pacific Psoriatic Arthritis Therapeutics Market Report:
Asia Pacific grows from $2.35 Billion in 2023 to $5.45 Billion in 2033. Growth is driven by expanding healthcare access, rising diagnosis rates, and growing availability of advanced therapies and biosimilars across multiple markets in the region.North America Psoriatic Arthritis Therapeutics Market Report:
North America is largest regional market, rising from $4.65 Billion in 2023 to $10.78 Billion in 2033. Regional strength is linked to established healthcare infrastructure, high uptake of advanced biologics, and significant clinical research activity supporting new therapeutic adoption.South America Psoriatic Arthritis Therapeutics Market Report:
Latin America grows from $1.17 Billion in 2023 to $2.72 Billion in 2033. The regional outlook reflects improving access to specialized care, gradual uptake of newer therapeutics, and policy initiatives that broaden treatment availability.Middle East & Africa Psoriatic Arthritis Therapeutics Market Report:
Middle East and Africa grows from $0.64 Billion in 2023 to $1.48 Billion in 2033. Market development is influenced by expanding healthcare infrastructure, growing awareness of psoriatic arthritis, and gradual introduction of advanced therapeutic options.Tell us your focus area and get a customized research report.
Research Methodology
Psoriatic Arthritis Therapeutics Market Analysis By Drug Class
In 2023, the market for Disease-Modifying Antirheumatic Drugs (DMARDs) is valued at $7.48 billion, holding a 62.35% share. This segment is projected to reach $17.37 billion by 2033, reflecting the efficacy of DMARDs in providing long-term relief and managing disease progression. Non-steroidal Anti-Inflammatory Drugs (NSAIDs) will reach $8.02 billion by 2033 from $3.45 billion in 2023, maintaining a steady share of 28.78%. Corticosteroids, while smaller with $1.06 billion in 2023, are expected to rise to $2.47 billion, representing 8.87% by 2033.
Psoriatic Arthritis Therapeutics Market Analysis By Route Of Administration
The oral route dominates with $7.48 billion in 2023 and a share of 62.35%, while injections and topical formulations contribute $3.45 billion and $1.06 billion, respectively. By 2033, oral administration will maintain its leading position, projected at $17.37 billion, while injections and topical revenues are anticipated at $8.02 billion and $2.47 billion.
Psoriatic Arthritis Therapeutics Market Analysis By Patient Type
For adult patients, the market is currently valued at $10.09 billion and is projected to reach $23.43 billion by 2033, capturing an overwhelming 84.12% of the market. Pediatric patients, currently at $1.91 billion, are expected to grow to $4.42 billion, making up 15.88% of the market share.
Psoriatic Arthritis Therapeutics Market Analysis By Indication
The market for mild psoriatic arthritis currently accounts for $7.48 billion and is expected to grow exponentially to $17.37 billion by 2033, sharing 62.35%. Moderate and severe cases are projected to reach $8.02 billion and $2.47 billion, respectively, indicating the need for targeted therapies as disease severity increases.
Psoriatic Arthritis Therapeutics Market Analysis By Distribution Channel
Retail pharmacies, holding a size of $7.48 billion (62.35% share) in 2023, are expected to grow to $17.37 billion by 2033. Hospital pharmacies and online pharmacies will also capture significant market segments at $8.02 billion and $2.47 billion respectively, by that year.
Psoriatic Arthritis Therapeutics Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Psoriatic Arthritis Therapeutics Industry
AbbVie:
AbbVie is a global biopharmaceutical company leading in research and development of innovative treatments for psoriatic arthritis, particularly with drugs like Humira and Rinvoq.Johnson & Johnson:
Johnson & Johnson focuses on developing comprehensive therapeutics for autoimmune diseases, with drugs like Tremfya addressing psoriatic arthritis.Amgen:
Amgen is known for its advanced biologics including Enbrel, a key treatment for psoriatic arthritis, enhancing patient outcomes.Novartis:
Novartis provides a range of innovative medications targeting various aspects of psoriatic arthritis, including Cosentyx, which has significantly improved therapy options.We're grateful to work with incredible clients.
FAQs
What is the market size of the Psoriatic Arthritis Therapeutics Market Report in 2023?
The market size for 2023 is $12.00 Billion, as reported for the Psoriatic Arthritis Therapeutics Market Report, reflecting baseline industry valuation at the start of the forecast period.
How big will the market be by 2033?
By 2033 the market is projected to reach $27.85 Billion according to the provided forecast, representing the expected end-period market valuation under current assumptions.
What is CAGR for the forecast period?
The compound annual growth rate (CAGR) for 2023 to 2033 is 8.5%, as specified for the market over the ten-year forecast interval.
Which companies are identified as top players?
Top companies listed in the report include AbbVie, Johnson & Johnson, Amgen, and Novartis, reflecting prominent participants in therapeutics development and commercialization.
Is there a single fastest Growing region in the Psoriatic Arthritis Therapeutics Market Report market?
No single fastest-growing region is stated for the Psoriatic Arthritis Therapeutics Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
What are primary therapeutic classes covered?
The report covers key drug classes such as Disease-Modifying Antirheumatic Drugs (DMARDs), Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), and corticosteroids across multiple delivery routes.
How are distribution channels addressed?
Distribution channels include pharmacies, hospital pharmacies, and online pharmacies, reflecting the variety of points of care and access for patients and prescribers.
Who contributed to the report research?
Research was conducted using primary interviews with industry experts and secondary sources such as company reports and publications, with data triangulation and internal validation.
What patient segments are analyzed?
Patient-type segmentation includes adult patients and pediatric patients, enabling assessment of treatment patterns and demand across age cohorts.
Which routes of administration are included?
Routes of administration analyzed encompass oral, injection, and topical forms, covering the main therapeutic delivery options for psoriatic arthritis.